Related Experiment Video
Updated: Mar 18, 2026

Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
Published on: April 12, 2024
Growth Hormone Excess in Children with Optic Pathway Tumors Is a Transient Phenomenon
Jami L Josefson1, Robert Listernick, Joel Charrow
1Division of Endocrinology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill., USA.
Insights
Growth hormone (GH) excess in children with optic pathway tumors (OPT) is often overlooked. In a study of 7 children, GH excess resolved in most cases, suggesting treatment benefits may be unclear.
Area of Science:
- Pediatric Endocrinology
- Neuro-oncology
- Genetics
Background:
- Growth hormone (GH) excess is underrecognized in children with chiasmal optic pathway tumors (OPT), frequently linked to neurofibromatosis type 1 (NF1).
- These children exhibit elevated insulin-like growth factor 1 (IGF-1) and rapid growth despite precocious puberty treatment.
- GH levels fail to suppress after an oral glucose challenge in affected children.
Purpose of the Study:
- To describe the treatment course and natural history of GH excess in children with OPT.
- To investigate the clinical presentation and biochemical evidence of GH excess in this pediatric population.
Main Methods:
- A descriptive case series included 7 children (5 previously described, 2 newly diagnosed).
- All patients presented with clinical and biochemical signs of GH excess.
- Treatment involved the somatostatin analog octreotide.
Main Results:
- Treatment duration varied among the 7 patients.
- Five out of seven patients achieved resolution of GH excess.
- These 5 patients normalized IGF-1 levels without ongoing treatment.
Conclusions:
- A subset of children with OPT experience unrestrained GH secretion with potential adverse outcomes.
- GH excess appears to resolve spontaneously over time in these patients.
- The benefit of interventions like octreotide in altering outcomes or preventing tumor progression remains uncertain.
Background/Aims:
Growth hormone (GH) excess in children with chiasmal optic pathway tumors (OPT), often associated with neurofibromatosis type 1 (NF1), is likely underrecognized. These children have elevated insulin-like growth factor 1 (IGF-1) levels, evidence of rapid growth despite treatment of precocious puberty, and failure to suppress GH levels following oral glucose challenge. The aim of this report is to describe the treatment course and natural history of this rare clinical condition in 7 patients.
Methods:
This is a descriptive case series of 5 children previously described and 2 additional children more recently diagnosed at our institution. All 7 children had clinical and biochemical evidence of GH excess and received treatment with the somatostatin analog octreotide.
Results:
Length of treatment varied among the patients. Five of the 7 patients have had resolution of GH excess and currently have normal IGF-1 levels without treatment.
Conclusions:
Unrestrained GH secretion occurs in a subset of children with OPT with potential adverse outcomes. Since GH excess appears to resolve over time, the benefit of treatment to alter outcomes or prevent tumor progression is unclear.
Related Concept Videos
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
Nature and Nurture
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Hypoglycemia and Glucagon

